Little Green Pharma (LGP) subsidiary Reset Mind Sciences receives ethics approval to conduct a 12-month psilocybin clinical trial The trial will focus on the development and refinement of best-practice psychotherapy protocols to enable the administration of psilocybin for depression The trial follows the TGA’s recent decision to down-schedule psilocybin in defined circumstances for use with treatment-resistant depression The trial is set the first of its kind to be conducted in Western Australia using psilocybin LGP shares are up 2.44 per cent and trading at 21 cents at 2:11 pm AEDT
Source: The Market Herald